The Effects of Real-World Evidence on the Treatment of HER2+ mBC - Episode 9

Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Evolution of Advanced HER2+ Breast Cancer Management
    EP. 2: Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)
    EP. 3: The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC
    EP. 4: Approaches to Sequencing Therapies for HER2+ mBC
    EP. 5: Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC
    EP. 6: Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC
    EP. 7: Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment
    EP. 8: Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)
    Now Viewing
    EP. 9: Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan
    EP. 10: Novel Therapies Under Investigation for HER2+ mBC
    EP. 11: Treatment Sequencing Approaches for Patients With HER2+ mBC
    EP. 12: French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC
    EP. 13: Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
    EP. 14: Treatment Approaches for Patients With HER2+ mBC and Brain Metastases
    EP. 15: Novel Treatment Approaches Under Investigation for HER2+ mBC
    x